The blockbuster success of antibody-based therapeutics for autoimmune diseases, inflammatory diseases and immuno-oncology accelerated the high stakes monoclonal antibody (mAb) development race. Clone selection is a significant upstream bottle-neck slowing bench-to-bedside development progress for new mAb-based therapeutics.

Cy-Clone? PLUS, a validated assay kit accelerates human mAb production cell-line generation, significantly reducing the time to industrial-scale productivity. The Intellicyt? Cy-Clone PLUS assay combined with the Intellicyt? iQue platform with ForeCyt? Software are the powerful analytical tools that inform rapid go/no-go decisions with multiparameter, high-content data from a single-path workflow.

Learn more about Sartorius solutions for mAb Discovery & Development at www.sartorius.com/mab-oncology.

Complete the form below to download the white paper.